Anavex Life Sciences Corp (AVXL)

[rx7171]

In 2021 the good PDD Phase 2 data caused the company to spike to $27.
Nothing since then feels like a lost opportunity.

Missling has said that due to advanced PDD patients often having their drug dosages adjusted it would be very difficult to get a consistent placebo group comparison in a longer Phase 3.

They are now talking about running a regular PD trial that would not treat the highly advanced PDD patients.

With the cash on hand running two Phase 3’s sounds a stretch unless they get a partner.

Right now now my bet is on the company eventually submitting an NDA to the FDA within the next six months.